Parikh Anand Kiran 4

4 · Sensei Biotherapeutics, Inc. · Filed Jun 16, 2026

AI-generated summary of this filing

Updated Jun 16, 2026

Sensei CEO Anand Parikh Converts Preferred into 761,428 Shares

What Happened

Anand Parikh, President, CEO and Director of Sensei Biotherapeutics (FTH), recorded a conversion of derivative securities on 2026-06-15. The filing shows disposal of 761.428 shares of Series B Preferred (derivative) and acquisition of 761,428 shares of common stock. No cash price is reported (N/A).
Conversion math: each Series B Preferred share converts into 1,000 common shares per the Certificate of Designation, so 761.428 Series B Preferred → 761,428 common shares. This reflects a conversion related to the Merger described in the filing, not an open-market buy or sale.

Key Details

Transaction date: 2026-06-15; Form 4 filed: 2026-06-16 (timely).
Transaction code: C (conversion of derivative security).
Price: N/A — no cash paid/received in the conversion.
Shares recorded: Disposal of 761.428 Series B Preferred (derivative); Acquisition of 761,428 common shares.
Shares owned after transaction: not specified in the filing.
Notable footnotes:
- F1: Each Series B Preferred is convertible into 1,000 common shares and has no expiration.
- F2/F3: Conversion follows the February 17, 2026 Merger Agreement that resulted in HoldCo common being exchanged for 761.428 Series B Preferred shares.
Filing timeliness: filed the day after the transaction (appears timely under Form 4 rules).

Context

This was a conversion of a derivative (preferred) into common stock — a corporate capitalization event tied to the Merger — not a market purchase or sale. Such conversions are routine and do not by themselves indicate insider buying or selling sentiment.
The filing shows both the disposal of the derivative interest and the acquisition of common shares to reflect the change in holdings after conversion.

Form 4

Period: 2026-06-15

DirectorPresident and CEO

Transactions

Conversion
Common Stock
[F1][F2][F3]
2026-06-15+761,428→ 761,428 total
Conversion
Series B Preferred Stock
[F1][F2][F3]
2026-06-15−761.428→ 0 total
→ Common Stock (761,428 underlying)

Footnotes (3)

[F1]Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.
[F2]Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").
[F3]Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock.

Signature

/s/ Josiah Craver, Attorney-in-Fact|2026-06-16

1 file